Psychiatry has been held back by our limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of most commonly prescribed types of antidepressants treatment. Likewise, dopamine receptor antagonists are widely used to treat schizophrenia. Pierre Deniker and Jean Delay conducted a clinical trial at the Sainte-Anne Hospital Center in Paris in which they treated 38 psychotic patients with daily injections of chlorpromazine, a dopamine receptor antagonist, without the use of other sedating agents. The response was dramatic; treatment with chlorpromazine went beyond simple sedation with patients showing improvements in thinking and emotional behavior. That was first reported in 1952.

There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients that will result in better outcomes than what is provided by existing approaches. Translational Psychiatry bridges this gap by focusing on papers that directly study psychiatric disorders and bring new discovery into clinical practice. In addition to this core mission of the journal, we may consider papers from all areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging, and epidemiology, that have potential to contribute to enhance the field of translational psychiatry more broadly. To maintain balance, such papers that do not directly address our core mission will be considered on a case-by-case basis, as a matter of editorial discretion, which can also be supported by advice gained during the peer review process.

We are the highest-ranked open access journal in Psychiatry, with the aim of bridging the gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients.

Open access publication ensures that your article can be easily discovered, accessed, used, and shared, maximizing your impact and acting as a springboard for further discovery.

We provide a clear and supportive publication process, and ensure high visibility for your publication through our nature.com platform.

Our highly-respected editorial team leads a rigorous and rapid peer review process.

Journal metrics

The 2021 journal citation metrics for Translational Psychiatry are as follows:

2-year Impact Factor* (2022): 6.8
5-year Impact Factor* (2022): 7.0
Immediacy index*: 1.111
Eigenfactor® score*: 0.03067
Article influence score*: 2.171
JCR Rank*: PSYCHIATRY 24/156
Journal Citation Score*: 1.7

SNIP: 1.508
SJR: 2.652

*2020 Journal Citation Reports^® Science Edition (Clarivate Analytics, 2021)

• 1,417,295 Downloads

Speed:
15 days to first decision for all manuscripts (Median)
50 days to first decision for reviewed manuscripts only (Median)

Usage:
3,789,561 Downloads (in 2022)
10,415 Altmetric mentions (2021)

Abstracted/indexed in

PubMed/MEDLINE
PubMed Central
Scopus
ISI Web of Science
DOAJ
British Library
Crossref

ISSN and E-ISSN

The ISSN (online) number for Translational Psychiatry is 2158-3188.